Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofibromas; Expected To Complete By Q2 Of 2024

Author: Benzinga Newsdesk | March 04, 2024 07:37am

Posted In: SWTX